Chinese, Overweight or Obesity, Real-World Registry Study

Chinese Registry of Overweight or Obesity, a Multicenter Real-World Registry Study on Clinical Management - CROWN Study

This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide. At baseline, demographic data, physical examinations, multiple laboratory tests (including complete blood count, urinalysis, liver/renal function, electrolytes, thyroid function panel [3 items], urine albumin/creatinine ratio, fasting glucose, fasting C-peptide, fasting insulin, HbA1c, blood lipids, etc.) and hepatic elasticity ultrasound will be performed. Patients will receive weight-loss therapy in routine clinical practice. Data on clinic visits, adverse events, and changes in therapeutic regimens will be centrally collected by investigators or their authorized representatives at Week 26 and Week 52.

Study Overview

• Status: Not yet recruiting
• Conditions: Obesity Type 2 Diabetes Mellitus

Detailed Description

This is a prospective, multicenter registry study designed to investigate the clinical characteristics and prognosis of obese patients in China, which may provide insights and opportunities to narrow the gaps in obesity-related clinical practice and improve clinical practice standards in China. The study will recruit 10,000 subjects from weight management clinics or endocrinology departments of 50 tertiary or higher-level medical institutions nationwide and follow them up for one year.

Researchers will obtain informed consent for study participation from obese patients during routine clinical visits, after which patients will be enrolled and registered.

Subsequently, subjects will undergo a baseline visit and be invited to participate in this 1 year observational registry study. They will receive clinical evaluations and the treatment regimens prescribed by their treating physicians.

Following the scheduled baseline visit, subjects will continue to be followed up for 1 year through routine clinical care as part of this observational study, and all collected data will be uploaded to the registry center.

• Study Type: Observational
• Enrollment (Estimated): 10000

Contacts and Locations

• Study Contact: Name: MuYiming; Phone Number: 86+13910580089; Email: muyiming@301hospital.com.cn
• Study Contact Backup: Name: ChenKang; Phone Number: 010-55499401; Email: cycon_ck@yeah.net

Study Locations

• China
  • Being
    • Haidian, Being, China, 100039
      • Chinese PLA General Hospital
      • Contact: ChenKang; Phone Number: 010-55499401; Email: cycon_ck@yeah.net

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

1. Male or female patients over 18 years old
2. Diagnosed as overweight or obese, with a BMI of ≥ 24 kg/m²
3. Willing and able to use weight management apps
4. Willing and able to provide a written informed consent for participating in the study
5. Patients who meet the instructions for weight loss medication and have no contraindications to medication

Description

Inclusion Criteria:

According to local regulations, the subjects included in the study should meet the following criteria:

1. Male or female patients aged 18 years or above
2. Diagnosed with overweight or obesity, with a BMI of ≥ 24 kg/m²
3. Willing and able to use weight management apps
4. Willing and able to provide a written informed consent for participating in the study
5. Patients who meet the instructions for weight loss medication and have no contraindications to non-pharmacological treatments -

Exclusion Criteria:

1. Having life-threatening comorbidities, with an expected lifespan of less than one year.
2. Participating in an interventional trial that requires informed consent.
3. Engaging in other organized weight loss programs or other clinical trials.

4. Researchers identify any situation that may endanger the safety or compliance of the subjects.

   -

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The treatment model for overweight and obese individuals in China at present.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Observe the changes in liver fat content and liver stiffness in Chinese overweight and obese patients after 6 months and 12 months of follow-up: Liver stiffness measurement (LSM) and control attenuation index (Cap)		6 months and 12 months
Observe the changes in body weight after 6 months and 12 months of follow-up: BMI		6 months and 12 months
Evaluation of risk factors related to fatty liver disease in obesity combined with metabolic dysfunction		6 months and 12 months
Observe the changes in related metabolic indicators over 6 months and 12 months, including changes in indicators such as blood lipids, blood pressure, and blood sugar.		6 months and 12 months
Conduct a subset analysis for patients undergoing weight loss treatment with Mazdutide, analyzing related indicators including weight, metabolic indicators, cardiovascular and renal outcomes, and adverse reactions.		6 months and 12 months
Observe the social demographic and clinical characteristics of obese and overweight patients	Describe different social demographic characteristics (age, gender, race, education level, marital status, family history, physical activity, smoking history, alcohol consumption.; Describe different clinical characteristics (body mass index [BMI], body fat percentage, waist circumference, waist-to-hip ratio, waist-to-height ratio, duration of obesity, duration of fatty liver disease, the number, type, and prevalence of other obesity-related comorbidities: especially non-alcoholic fatty liver disease, polycystic ovary syndrome, sleep apnea syndrome, etc.); Compare the differences in demographic and clinical characteristics among different groups of patients with different regions, different degrees of obesity, etc.	6 months and 12 months
Observe the impact of different weight management methods on cardiovascular and renal outcomes and their risk factors.	Observe the changes in weight-related indicators and metabolic-related; Compare the differences in cardiovascular and renal outcomes among different populations.	6 months and 12 months

Other Outcome Measures

Outcome Measure	Time Frame
Analyze the impact of the frequency of patient usage and the use of different items (such as weight recording, body fat recording, recipe registration, exercise registration, etc.) on the outcome of the patient's weight management.	1 year

Collaborators and Investigators

• Sponsor: Chinese PLA General Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): May 30, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: March 18, 2026
• First Submitted That Met QC Criteria: April 10, 2026
• First Posted (Actual): April 13, 2026

Study Record Updates

• Last Update Posted (Actual): April 13, 2026
• Last Update Submitted That Met QC Criteria: April 10, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Real world study; Obesity Type 2 Diabetes Mellitus
• Other Study ID Numbers: S2025-730-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No